2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
2021 · Blood · 681 citations
https://doi.org/10.1182/blood.2021013626
P
Peter J.M. Valk
Erasmus MC(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
505
Papers
25.2K
Citations
73
h-index
191
i10-index
Peter J.M. Valk is an academic researcher from Erasmus MC. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Myeloproliferative Neoplasms: Diagnosis and Treatment & Protein Degradation and Inhibitors. The author has an h-index of 73, co-authored 430 publications.
ORCID: 0000-0002-8857-9461Papers by this author
worksCell of origin determines clinically relevant subtypes of MLL-rearranged AML
2012 · Leukemia · 201 citations
https://doi.org/10.1038/leu.2012.363
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
2020 · Science Translational Medicine · 200 citations
https://doi.org/10.1126/scitranslmed.aaz0463
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years
2014 · Leukemia · 129 citations
https://doi.org/10.1038/leu.2014.332
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates
2015 · Haematologica · 96 citations
https://doi.org/10.3324/haematol.2014.117424
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia
2008 · Leukemia · 83 citations
https://doi.org/10.1038/leu.2008.318
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat